Tharimmune Positive Phase 1 Data on Lead Candidate for Chronic Pruritis in Biliary Cholangitis

 

• Phase 1 ex-US trial achieved primary objective of predictable pharmacokinetic profiling with favorable safety and tolerability
• Company expects to engage FDA on Phase 2 trial design and expects topline data in 2024 for chronic pruritis
• First indication for chronic pruritis in PBC where 70% of patients suffer from intractable and debilitating itching with limited treatment options

https://www.accesswire.com/viewarticle.aspx?id=810126